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Previewsto interpret, because the CD28 activation
experiments were only done in vitro, and
OX40 exerted in vitro but not in vivo
effects. Finally, the tolerized cells were
found to harbor defects in calcium influx
and mitogen-activated protein kinase
phosphorylation, consistent with obser-
vations described earlier for adaptive
tolerance (Chiodetti et al., 2006).
As with any provocative study, ques-
tions are raised as well as answered.
Recently, TCR-mediated induction of E3
ubiquitin ligases such as Cbl-b, Itch, and
Grail has been suggested to mediate
inductionandmaintenanceofTcell anergy
(Mueller, 2004). It will be worthwhile to
determine whether the strong TCR
signaling and absence of costimulation
provided by eTACs actually lead to the
expression of these genes. Also important
will be determining whether or not the
unresponsiveness induced by eTACs isstable and/or progressive to apoptosis
or, alternatively, might be reversible by
inflammatory or growth-promoting cyto-
kines (Figure 1). Anergy induced by TCR
stimulation in theabsenceof costimulation
might be a metastable event in vivo ulti-
mately leading to cell death (Li et al.,
2001). Whether this occurred in the case
of eTACs could not be determined from
the present study, nor is it clear whether
delivery of CD28 costimulation in vivo will
block tolerance. The answer(s) to these
questions will be important if these find-
ings are to be harnessed into a potentially
new and ‘‘fresh’’ therapeutic approach
for autoimmunity and transplantation.
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Previous studies have highlighted the immune-dampening effects of apoptotic cell uptake by phagocytes.
Ohyagi et al. (2013) expose a unique mechanism of immune regulation during viral infection, which is medi-
ated through phagocytosis of apoptotic red cells by dendritic cells.Ideally, immunostimulatory and immuno-
regulatory factors during viral infection
should be balanced to allow for sufficient
generation of innate and adaptive immu-
nity to facilitate viral clearance, while
limiting uncontrolled immune activation
that can result in tissue damage and/or
death. Apoptotic cells (AC) have long
been recognized to participate in immune
regulation through their effects on phago-
cytic cells, including dendritic cells (DCs).
The induction of tolerogenic DCs by AC
bears important relevance to the fields
of autoimmunity and tumor immunology.In contrast, relatively little has been
described regarding the modulation of
immune responses by ACs throughout
the course of viral infections. In this issue
of Immunity, Ohyagi et al. (2013) describe
a process of imperfect compromise
between antiviral immune responses and
AC-mediated immune regulation. Secre-
tion of interleukin-10 (IL-10) by inflamma-
tory monocyte-derived dendritic cells
(Mo-DCs) as a consequence of hemopha-
gocytosis of apoptotic red blood cells
(RBC) protected mice from lethal inflam-
matory responses following injectionwith Toll-like receptor (TLR) agonists (pri-
marily CpG and poly I:C) or chronic lym-
phocytic choriomeningitis virus (LCMV)
infection. In the case of LCMV infec-
tion, there was elevated and persistent
viremia due to compromised immunity.
In this study, the authors have described
an unusual mechanism of immune regula-
tion during viral infection that provides
new perspectives on big picture ques-
tions regarding the complex interplay
between virus and host.
Ohyagi et al. have now demonstrated
that hemophagocytosis of apoptoticptember 19, 2013 ª2013 Elsevier Inc. 429
Figure 1. Immunomodulation by IL-10 following Hemophagocytosis by moDC
Elevations in type I IFN following viral infection or TLR ligation leads to increased RBC apoptosis and expo-
sure of PS, as well as upregulation of AC receptors (Tim 1, Tim4, aVb3 and aVb5) and MFG-E8 by moDC.
MFG-E8 facilitates binding of PS on ACs to aVb3 and aVb5 integrins followed by engulfment and IL-10
secretion. IL-10 and downstream effects result in blunting and exhaustion of CTLs and poor viral control
but mitigation of host injury and death (blue panel). The converse is observed when IL-10 signaling is
partially disrupted via (1) genetic deletion of IL-10 in moDC, (2) blockade of hemophagocytosis with AC
receptor antibodies, or (3) IL-10-blocking antibodies (pink panel).
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PreviewsRBC, following strong Toll-like receptor
(TLR) stimulation or LCMV infection, is
responsible for secretion of IL-10 by
inflammatory moDCs that are rapidly re-
cruited from the bone marrow (Ohyagi
et al., 2013). Transforming growth factor-
b (TGF-b) concentrations also rose and
were reliant upon IL-10 secretion following
hemophagocytosis. They further identified
hemophagocytosis by moDCs to be
dependent upon type I interferon (IFN)
signaling that promoted apoptosis and
exposure of phosphatidylserine (PS, ‘‘eat
me’’ signal) primarily on RBC, as well as
upregulation of AC receptors on moDCs.
During LCMV infection, hemophagocyto-
sis and IL-10 secretion were significantly
decreased upon blockade of multiple AC
receptors simultaneously (Tim 1, Tim4,430 Immunity 39, September 19, 2013 ª2013aVb3andaVb5),with little effectuponblock-
ing Tim1 and Tim4 individually. In vitro
experiments further confirmed that these
processes were primarily dependent
upon PS binding to integrins (aVb3 and
aVb5) viamilk-fat globule epidermal growth
factor (EGF) factor 8 (MFG-E8), a protein
that bridgesPS-expressing AC to integrins
onDCs. Though alphaV integrins, in partic-
ular aVb8, have also been implicated in
enhancement of TGF-b secretion by DC
leading to T regulatory cell development
in mouse models of mucosal tolerance
(Travis et al., 2007), here the authors
describe immunomodulation of moDC
function following binding to aVb3 or aVb5
integrins by AC. Furthermore, the findings
by Ohyagi et al. (2013) add to the small
but growing body of literature implicatingElsevier Inc.AC as a means to modulate immune func-
tion during chronic viral infections and
identify RBC as a significant, unexpected
source of AC in their model. Recently,
Frleta et al. (2012) reported that apoptotic
microparticles from dying cells found
circulating during acute HIV-1 infection
inhibit moDC function by abrogating
secretion of proinflammatory cytokines
and T cell priming capacity. In contrast to
the current study, this process is not found
tobemediatedbybinding to classicAC re-
ceptors onmoDC or associated with IL-10
secretion. Rather, apoptoticMPs bind and
inhibit DCs via the hyaluronate receptor
CD44 and induce the production of TGF-b.
Whether ‘‘good’’ or ‘‘bad,’’ it is clear
that a lot hinges on IL-10 in the chronic
LCMV model. In seminal studies by
Brooks et al. (2006), it was determined
that secretion of IL-10 by infected
CD8a-CD4+ DCs facilitates the establish-
ment of chronic infection by the clone 13
variant, and its blockade enhances adap-
tive immunity and viral clearance. IL-10 is
known to dysregulate DC function and
drive T cells toward ‘‘exhaustion.’’ Recent
studies have established the dependence
of DC IL-10 secretion on type I IFN
signaling during chronic LCMV infection
(Teijaro et al., 2013). Ohyagi et al. now
provide a mechanistic link between type
I IFN and IL-10 and in many ways support
these prior studies but reveal an unex-
pected outcome. Here, despite enhanced
cytotoxic T lymphocyte (CTL) function
and improved viral control following
conditional deletion of Il10 in CD11c+
DCs, viral infection did not resolve as
has been previously demonstrated upon
disruption of IL-10 signaling (Ohyagi
et al., 2013, Brooks et al., 2006). Instead,
thesemice displayed heightened damage
to tissues and increased mortality attrib-
uted to unchecked inflammation (Figure 1)
(Ohyagi et al., 2013). IL-10, therefore,
confers a host survival benefit by miti-
gation of immune-mediated injury. The
contribution of direct LCMV infection in
inflammatory moDCs to hemophagocy-
tosis and IL-10 production (not directly
assessed here), remains unclear, despite
the fact that DCs are the major IL-10 pro-
ducing and virus-infected cells in vivo
(Brooks et al., 2006). Given that strong
TLR signaling also induces hemophago-
cytosis and IL-10 (Ohyagi et al., 2013),
antigen seems to be irrelevant. Rather, it
is possible that viral RNA elicits
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ferentiation primary response gene 88
(MyD88), recently identified to be neces-
sary for the development of hemophago-
cytic lymphohistiocytosis (Krebs et al.,
2011), and resultant type I IFN production.
The effects observed upon inflammatory
moDCs therefore might be an indirect
consequence of LCMV infection.
The divergent outcomes of tissue injury
and mortality following disruption of Il10
between the current study and previously
established findings in the LCMV model
call for some speculation relating to how
themagnitudeof IL-10disruptionmight in-
fluence the course of disease.One keydif-
ference is that Ohyagi et al. eliminate IL-10
secreting capacity only in CD11c+ DCs
versus complete genetic deletion of Il10
as has been previously studied (Brooks
et al., 2006), leaving significant residual
amounts in the blood (approximately
30% of WT). This decrement in IL-10 was
partially effective in boosting virus-spe-
cific cytolytic T cell (CTL) number and
reducing circulating virus, however, it
was not sufficient for viral clearance
(Ohyagi et al., 2013). In the setting of
now-lowered concentrations of immuno-
regulatory factors, this resulted in promot-
ing tissue inflammation, injury, and death.
On the other hand, in the complete
absence of IL-10, T cell exhaustion is
averted, effector T cell responses are
established, and virus is quickly cleared
with minimal tissue injury (Brooks et al.,
2006). Therefore, the concentrations of
immunoregulatory factors that are eli-
cited during viral infection, and their main-
tenance, might ultimately determine the
host’s outcome. Parallel concepts exist
in models of pathogenic versus non-
pathogenic SIV in nonhuman primates.
Although both develop chronic infection
with sustained viremia, nonpathogenic
infection is marked by the upregulation of
a distinct set of immunoregulatory re-
sponses including IL-10 and TGF-b. In
contrast, the absence of these dampening
factors along with sustained type I IFN
signaling leads to chronic immune acti-
vation and development of immuno-
deficiency in pathogenic SIV infection
(Jacquelin et al., 2009).
Immune regulation in the acute phase
of infection might be necessary at times
to alleviate mortality from immunopa-
thology while facilitating viral persistence.
It remains possible that opportunitiesfor intervention exist during the chronic
phases of disease to relieve immune
exhaustion and enhance viral control.
The critical importance of timing is high-
lighted in a study of blockade of the inhib-
itory ligand receptor pair, PD-1/PD-L1,
during LCMV infection (Barber et al.,
2006). Whereas infection of Cd274/
mice results in early mortality similar to
results of Il10/ moDC seen by Ohyagi
et al. (2013), blockade of PD-L1 later in
course of infection relieved CTL exhaus-
tion and lowered viral load. Similarly,
positive effects on immune function, viral
control, and survival are observed in
the chronic SIV model following PD-1
blockade when antibodies are adminis-
tered even 10 weeks after infection (Velu
et al., 2009). Moreover, IL-10R and type I
interferon receptor (IFNAR1) blockade in
the persistent phase of LCMV infection
has been shown to improve viral control
and decrease T cell exhaustion in the
case of IL-10 neutralization (Teijaro
et al., 2013, Brooks et al., 2006). Future
work to fine-tune the kinetics of hemo-
phagocytosis and IL-10 blockade during
LCMV infection in this model is war-
ranted to determine whether disruption
of signaling at later phases of infection
would be of overall benefit.
Overt, symptomatic hemophagocytic
syndrome (HPS) is a clinical disorder
that is associated with infection, genetic
defects, malignancy, and autoimmune
disease. It is characterized by uncon-
trolled activation of lymphocytes and
monocytes, elevated serum cytokines,
multiorgan dysfunction, and often death,
some features of which manifest in
chronic LCMV infection. HPS’s hallmark
is phagocytosis of various blood cells by
reactive histiocytes in the bone marrow
and other lymphoid tissue. Commonly
assumed to drive the pathology, the sig-
nificance of this feature in disease patho-
genesis remains unclear. Though HPS
is a rare complication of chronic infec-
tions, preliminary evidence suggests that
lower level, subclinical hemophagocyto-
sis might occur more frequently during
chronic infections including HIV. Given
the link between type I IFN and IL-10
induction, it is interesting to speculate
whether type I IFN elicited during the
course of infection programs for HPS
and possibly IL-10 production, by pro-
moting apoptotic cell death and phago-
cytic cell uptake of AC. IL-10 can beImmunity 39, Seelevated in infections such as HIV, though
its exact role(s) in immunopathogenesis
and regulation during the various phases
of infection have yet to be clearly defined.
Preliminary studies in HIV again support
the notion that timing is critical when it
comes to immune regulation. Human IL-
10 promoter polymorphisms resulting in
higher IL-10 production have been shown
to correlate with elevated viral loads dur-
ing acute infection but might protect
against CD4+ T cell loss and disease
progression during later stages of infec-
tion (Naicker et al., 2009). A greater under-
standing of these kinetics in various viral
infections and the underlying mecha-
nisms that govern secretion would be
helpful in determining the possible thera-
peutic utility of cleaning up the ‘‘bloody
mess’’ elicited during infection.REFERENCES
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